目的研究肝癌根治性切除术后肝动脉化疗栓塞，联合LAK细胞/IL-2肝动脉灌注的价值。方法将42例肝癌根治性切除患者随机分为观察组和对照组。肝癌根治性切除术后肝动脉化疗栓塞，联合LAK细胞/IL-2肝动脉灌注患者21例为观察组；肝癌根治性切除术后单纯肝动脉化疗栓塞患者21例为对照组。结果观察组１年、２年、３年的肝内复发率（0、19.05%、57.14%）较对照组（28.57%、47.62%、85.71%）降低（χ2值分别是4.86、3.86、4.20，P＜0.05）；观察组２年、３年的生存率（85.71%、61.90%）较对照组（57.14%、28.57%）提高（χ2值分别是4.20、4.71，P＜0.05）。结论肝癌根治性切除术后肝动脉化疗栓塞，联合LAK细胞/IL-2肝动脉灌注是控制肝内复发率，提高患者生存率的有价值的治疗方法。%Objective To evaluate the effects of hepatic artery chemotherapeutic embolization combined with purfusing LAK cells/interleukin 2 into hepatic artery after radical operation of liver cancer. Methods Random divide 42 cases into two groups who had accepted radical operation of liver cancer: 21 cases who accepted hepatic artery chemotherapeutic embolization combined with purfusing LAK cells/interleukin 2 into hepatic artery as observing group, 21 cases accepted simply hepatic artery chemotherapeutic embolization as control group. Results The intrahepatic recurrence rates of 1, 2, and 3 years were 0, 19.05%, 57.14% in observing group, lower than 28.57%, 47.62%, 85.71% of control group (χ2=4.86, 3.86 and 4.20 respectively, P<0.05). The survival rates of 2 and 3 years were 85.71%, 61.90% in observing group, higher than 57.14%, 28.57% of control group (χ2=4.20 and 4.71, P<0.05). Conclusion Hepatic artery chemotherapeutic embolization combined with perfusing LAK cells/interleukin 2 into hepatic artery is an effective therapeutic method to control intrahepatic recurrence rates and raise the survival rates of the patients.
展开▼
